(19)
(11) EP 2 034 975 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.05.2012 Bulletin 2012/20

(45) Mention of the grant of the patent:
11.04.2012 Bulletin 2012/15

(21) Application number: 07809672.4

(22) Date of filing: 19.06.2007
(51) International Patent Classification (IPC): 
A61K 9/50(2006.01)
(86) International application number:
PCT/US2007/014282
(87) International publication number:
WO 2007/149438 (27.12.2007 Gazette 2007/52)

(54)

PHARMACEUTICAL COMPOSITIONS

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

COMPOSITIONS PHARMACEUTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 19.06.2006 US 814949 P

(43) Date of publication of application:
18.03.2009 Bulletin 2009/12

(60) Divisional application:
12153443.2

(73) Proprietor: Alpharma Pharmaceuticals, LLC
Bridgewater, NJ 08807 (US)

(72) Inventors:
  • MATTHEWS, Frank
    Bridgewater, NJ 08807 (US)
  • BOEHM, Garth
    Bridgewater, NJ 08807 (US)
  • TANG, Lijuan
    Bridgewater, NJ 08807 (US)
  • LIANG, Alfred
    Bridgewater, NJ 08807 (US)

(74) Representative: Lawrence, Malcolm Graham et al
avidity IP Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ
Epping, Essex CM16 5DQ (GB)


(56) References cited: : 
EP-A- 0 271 193
WO-A-2005/081825
US-A- 5 958 459
US-A1- 2003 124 185
 WO-A-2005/055981
WO-A-2007/145863
US-A1- 2003 004 177
US-A1- 2004 254 208
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).